

Reduced Calorie Intake and Weight Loss During Vagal Blocking in Subjects with Obesity-Related Type 2 Diabetes Mellitus

DESCRIPTION

Prospective, single-center, obese subjects with DM2	10 subjects 1 center
12-month follow-up	

RESULTS & SUMMARY

Obese patients with DM2 achieved reduced caloric intake, weight loss, and experienced enhanced satiety during 12 months of vBloc therapy.

Parameters	Wk 4	Wk 12	Mo 6	Mo 12
Calorie Intake (%)	-45	-48	-37	-30

- + DM2 subjects achieved mean EWL of 33%
- + Caloric consumption reduction by at least 30%

To learn more, visit www.vBloc.com



EnteroMedics, Inc.
2800 Patton Road
St. Paul, MN 55113 USA

TEL: 651.634.3003
FAX: 651.634.3212

The Maestro® Rechargeable System is indicated for use in weight reduction in patients aged 18 years through adulthood who have a Body Mass Index (BMI) of 40 to 45 kg/m², or a BMI of 35 to 39.9 kg/m² with one or more obesity related co-morbid conditions, and have failed at least one supervised weight management program within the past five years. The device should not be implanted in patients with cirrhosis, portal hypertension, esophageal varices or a significant hiatal hernia; patients for whom magnetic resonance imaging (MRI) or diathermy is planned; patients with an implanted electrical medical device or gastrointestinal device or prosthesis.

The most common related adverse events include pain, heartburn, nausea, dysphagia, eructation, and abdominal cramping.

Carefully read the product instruction manuals for complete safety information.

vBloc and Maestro are trademarks of EnteroMedics, Inc.

© 2015 EnteroMedics, Inc. All rights reserved.